Draft guideline on the investigation of interactions in the gastrointestinal tract

HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 November 2026 to 13 November 2026

Referral: Veterinary medicinal products containing amoxicillin, amoxicillin Article 141(1)(i) procedures Under evaluation, 10/09/2026

Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation: 01/02/2016, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 20, Status: Authorised

First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 October 2026, 15:30 (CEST) to 5 October 2026, 17:30 (CEST)

Fifth European Medicines Agency (EMA) - Vaccines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 October 2026, 14:00 (CET) to 26 October 2026, 16:00 (CET)